Endophthalmitis associated with intravitreal injections

International Ophthalmology Clinics

Volumn 47, Issue 2, 2007, Pages 199-208

  Ho, Janie ^a   Loewenstein, John I ^a  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANTIVIRUS AGENT; FOSCARNET; GANCICLOVIR; HYALURONIDASE; METHOTREXATE; NEOMYCIN; PEGAPTANIB; POVIDONE IODINE; RANIBIZUMAB; SODIUM CHLORIDE; SULFUR HEXAFLUORIDE; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN;

ADJUVANT THERAPY; CLINICAL TRIAL; DIABETIC MACULAR EDEMA; ENDOPHTHALMITIS; HUMAN; LYMPHOMA; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; RETINITIS; RETINOPEXY; REVIEW; STREPTOCOCCUS MITIS; UVEITIS; VITREOUS HEMORRHAGE;

ENDOPHTHALMITIS; HUMANS; INJECTIONS; VITREOUS BODY;

EID: 34248212737     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/IIO.0b013e318037795f     Document Type: Review

References (41)

1. Tornambe PE, Hilton GF. The Retinal Detachment Study Group. Pneumatic retinopexy. A multicenter randomized controlled clinical trial comparing pneumatic retinopexy with scleral buckling. Ophthalmology. 1989;96:772-784.
2. Hilton GF, Kelly NE, Salzano TC, et al. Pneumatic retinopexy. A collaborative report of the first 100 cases. Ophthalmology. 1987;94:307-314.
3. Eckart C. Staphylococcus epidermidis endophthalmitis after pneumatic retinopexy [Letter]. Am J Ophthalmol. 1987;103:720-721.
4. Hattenbach LO, Klais C, Koch FH, et al. Intravitreous injection of tissue plasminogen activator and gas in the treatment of submacular hemorrhage under various conditions. Ophthalmology. 2001;108:1485-1492.
5. Handwerger BA, Blodi BA, Chandra SR, et al. Treatment of submacular hemorrhage with low-dose intravitreal tissue plasminogen activator injection and pneumatic displacement. Arch Ophthalmol. 2001;119:28-32.
6. Hassan AS, Johnson MW, Schneiderman TE, et al. Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement. Ophthalmology. 1999;106:1900-1907.
7. Vote BJ, Buttery R, Polkinghorne PJ. Endophthalmitis after intravitreal injection of frozen preprepared tissue plasminogen activator (tPA) for pneumatic displacement of submacular hemorrhage. Retina. 2004;24:808-809.
8. Lahey JM, Fong DS, Kearney J. Intravitreal tissue plasminogen activator for acute central retinal vein occlusion. Ophthalmic Surg Lasers. 1999;30:427-434.
9. Kuppermann BD, Thomas EL, de Smet MD, et al. The Vitrase for vitreous hemorrhage study groups. Safety results of two Phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase®) for the management of vitreous hemorrhage. Am J Ophthalmol. 2005;140:585-597.
10. Smith JR, Rosenbaum JT, Wilson DJ, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology. 2002;109:1709-1716.
11. Baudouin C, Chassain C, Caujolle C, et al. Treatment of cytomegalovirus retinitis in AIDS patients using intravitreal injections of highly concentrated ganciclovir. Ophthalmologica. 1996;210:329-335.
12. Young S, Morlet N, Besen G, et al. High-dose (2000-μg) intravitreous ganciclovir in the treatment of cytomegalovirus retinitis. Ophthalmology. 1998;105:1404-1410.
13. Cochereau-Massin I, Lehoang P, Lautier-Frau M, et al. Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology. 1991;98:1348-1355.
14. Hodge WG, Lalonde RG, Sampalis J, et al. Once-weekly intraocular injections of ganciclovir for maintenance therapy of cytomegalovirus retinitis: clinical and ocular outcome. J Infect Dis. 1996;174:393-396.
15. Young SH, Morlet N, Heery S, et al. High dose intravitreal ganciclovir in the treatment of cytomegalovirus retinitis. Med J Aust. 1992;157:370-373.
16. Cantrill HL, Henry K, Melroe NH, et al. Treatment of cytomegalovirus retinitis with intravitreal ganciclovir. Ophthalmology. 1989;96:367-374.
17. Heinemann MH. Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy. Arch Ophthalmol. 1989;107:1767-1772.
18. Taskintuna I, Rahhal FM, Rao NA, et al. Adverse events and autopsy findings after intravitreous cidofovir (HPMPC) therapy in patients with acquired immune deficiency syndrome. Ophthalmology. 1997;104:1827-1837.
19. The Vitravene Study Group. Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol. 2002;133:484-498.
20. Ausayakhun S, Watananikorn S, Ngamtiphakorn S, et al. Intravitreal foscarnet for cytomegalovirus retinitis in patients with AIDS. J Med Assoc Thai. 2005;88:103-107.
21. Jager RD, Aiello LP, Patel SC, et al. Risks of intravitreous injection: a comprehensive review. Retina. 2004;24:676-698.
22. Engstrom RE, Holland GN. Local therapy for cytomegalovirus retinopathy. Am J Ophthalmol. 1995;120:376-385.
23. Moshfeghi DM, Kaiser PK, Scott IU, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol. 2003;136:791-796.
24. Westfall AC, Osborn A, Kuhl D, et al. Acute endophthalmitis incidence - intravitreal triamcinolone. Arch Ophthalmol. 2005;123:1075-1077.
25. Nelson ML, Tennant MT, Sivalingam A, et al. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina. 2003;23:686-691.
26. Moshfeghi AA, Scott IU, Flynn HW, et al. Pseudohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular edema. Am J Ophthalmol. 2004;138:489-492.
27. Roth DB, Chieh J, Spirn MJ, et al. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol. 2003;121:1279-1282.
28. Sutter FK, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment. Three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology. 2004;111:2044-2049.
29. Gillies MC, Simpson JM, Billson FA, et al. Safety of an intravitreal injection of triamcinolone - results from a randomized clinical trial. Arch Ophthalmol. 2004;122:336-340.
30. Jonas JB, Kreissig I, Degenring RF. Endophthalmitis after intravitreal injection of triamcinolone acetonide. Arch Ophthalmol. 2003;121:1663-1664.
31. Gragoudas ES, Adamis AP, Cunningham ET, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-2816.
32. Macugen Diabetic Retinopathy Study Group. A Phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005;112:1747-1757.
33. Heier JS, Antosyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration. A Phase I/II multicenter, controlled, multidose study. Ophthalmology. 2006. [Epub ahead of print].
34. Eifrig CW, Flynn HW, Scott IU, et al. Acute-onset postoperative endophthalmitis: review of incidence and visual outcomes (1995-2001). Ophthalmic Surg Lasers. 2002;33:373-378.
35. Wu PC, Kuo HK, Li M, et al. Nosocomial postoperative endophthalmitis: a 14-year review. Graefe's Arch Clin Exp Ophthalmol. 2005;1-10. [Epub ahead of print].
36. Miller JJ, Scott IU, Flynn HW, et al. Acute-onset endophthalmitis after cataract surgery (2000-2004): incidence, clinical settings, and visual acuity outcomes after treatment. Am J Ophthalmol. 2005;139:983-987.
37. Eifrig CW, Scott IU, Flynn HW, et al. Endophthalmitis after pars plana vitrectomy: incidence, causative organisms, and visual acuity outcomes. Am J Ophthalmol. 2004;138:799-802.
38. Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study: a randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol. 1995;113:1479-1496.
39. Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreous injections. Retina. 2004;24:S3-S19.
40. Ta CN. Minimizing the risk of endophthalmitis following intravitreous injections. Retina. 2004;24:699-705.
41. Ciulla TA, Starr MB, Masket S. Bacterial endophthalmitis prophylaxis for cataract surgery. Ophthalmology. 2002;109:13-26.